Clearbridge Investments LLC Buys 9371 Shares of Novadaq Technologies Inc (NASDAQ:NVDQ)

Remigio Civitarese
Luglio 16, 2017

The share price of the company (NVDQ) was up +0.09%, with a high of 11.74 during the day and the volume of Novadaq Technologies Inc shares traded was 3702755. As of June 30th, there was short interest totalling 1,862,039 shares, a decline of 64.4% from the June 15th total of 5,230,976 shares. Accern also gave press coverage about the medical research company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. The stock gained 3.83% or 0.09 points.

Hedge funds and other institutional investors have recently modified their holdings of the stock. The Company's SPY fluorescence imaging technology platform provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic.

More recent Novadaq Technologies Inc. Moreover, Frontier Capital Management Co Llc has 0.04% invested in the company for 4.17 million shares. Novadaq Technologies Inc.is headquartered in Mississauga, Canada. Elk Creek Partners LLC now owns 2,703,682 shares of the medical research company's stock valued at $21,062,000 after buying an additional 174,499 shares during the last quarter. Elk Creek Partners LLC boosted its position in Novadaq Technologies by 6.9% in the first quarter.

It closed at $11.72 lastly. The stock of Novadaq Technologies Inc.

Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) last issued its quarterly earnings data on Wednesday, May 3rd. Novadaq Technologies has a 12-month low of $5.84 and a 12-month high of $12.74. The firm has a 50-day moving average of $8.20 and a 200 day moving average of $7.47. It has a market capitalization of $677.49 million. ValuEngine upgraded Novadaq Technologies from a sell rating to a hold rating in a research note on Thursday, June 22nd. The medical research company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.03. Novadaq Technologies had a negative net margin of 71.97% and a negative return on equity of 49.93%. After posting $-0.24 EPS for the previous quarter, Novadaq Technologies Inc.'s analysts now forecast -12.50 % EPS growth.

Several equities analysts have recently commented on the stock.

Shares of Novadaq Technologies (NASDAQ:NVDQ) traded up 0.09% during midday trading on Thursday, hitting $11.73.

Canaccord Genuity downgraded Novadaq Technologies from a "buy" rating to a "hold" rating and set a $11.75 price objective for the company.in a research note on Monday. Craig Hallum downgraded Novadaq Technologies from a buy rating to a hold rating and set a $11.75 price target on the stock.in a research note on Monday, June 19th. Northland Capital maintained the shares of NVDQ in report on Monday, June 19 with "Hold" rating. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the stock. The stock exchanged hands 3.7 Million shares versus average trading capacity of 1.01 Million shares. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & global copyright legislation. Wedbush initiated Novadaq Technologies Inc. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE